EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression

Amanda E Downey, Balázs Szigeti, Ellen R Bradley, Gisele Fernandes-Osterhold, Kimberly Sakai, Katiah Llerena, Lisa Fredenburg, Jerusalem Nerayo, Lilly Evans-Riera, Brittany Nielsen, Andrew D Krystal, Aoife O'Donovan und 2 weitere

The Journal of Clinical Psychiatry · 2026

DOI: 10.4088/jcp.25m16227 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Clinical Psychiatry, 2026. Verfasst von Amanda E Downey und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational Psychedelic Research Program, Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of Califo…. Hauptthemen laut MEDLINE: Bipolar Disorder, Hallucinogens, Psilocybin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to concerns about precipitating mania or psychosis. The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of psilocybin therapy in individuals with BD-II and depression.

Methods

We conducted an open-label, single-arm pilot trial from 2022-2025 in which 14 participants with BD-II depression, diagnosed using adapted criteria requiring ≥2 consecutive days of hypomanic symptoms, received 10 mg of psilocybin, followed by 25 mg if symptoms persisted. Participants completed psychotherapy before, during, and after psilocybin sessions and were proactively monitored for adverse events. Depression and quality of life were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS; primary end point 21 days after each participant's final administration session) and the Quality of Life in Bipolar Disorder Questionnaire (QoL-BD), alongside exploratory measures.

Results

Psilocybin was well tolerated, with only transient increases in heart rate and blood pressure and no serious adverse events. Common side effects included mild-to-moderate anxiety, nausea, and headache. Three participants experienced notable psychiatric events (suicidal ideation or hypomania), which resolved with support. Following the 10 mg session, MADRS scores improved significantly (-12.7 [2.7], P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderHallucinogensPsilocybinAdultFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugPilot ProjectsPsychiatric Status Rating ScalesQuality of LifeTreatment Outcome

Substanzen

HallucinogensPsilocybin

Autor:innen und Institutionen

  • Translational Psychedelic Research Program, Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco.
  • Department of Pediatrics, University of California, San Francisco.
  • Centre for Psychedelic Research, Imperial College London, United Kingdom.
  • Parkinson's Disease Research, Education, and Clinical Center, San Francisco Veterans Affairs Medical Center, San Francisco, California.
  • San Francisco Veterans Affairs Medical Center, San Francisco, California.
  • Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco.

Zitieren

APA

Downey, A. E., Szigeti, B., Bradley, E. R., Fernandes-Osterhold, G., Sakai, K., Llerena, K., Fredenburg, L., Nerayo, J., Evans-Riera, L., Nielsen, B., Krystal, A. D., O'Donovan, A., Gard, D. E., & Woolley, J. D. (2026). An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m16227

Vancouver

Downey AE, Szigeti B, Bradley ER, Fernandes-Osterhold G, Sakai K, Llerena K, et al. An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression. The Journal of Clinical Psychiatry. 2026. doi:10.4088/jcp.25m16227

BibTeX
@article{Downey2026,
  author = {Downey, Amanda E and Szigeti, Balázs and Bradley, Ellen R and Fernandes-Osterhold, Gisele and Sakai, Kimberly and Llerena, Katiah and Fredenburg, Lisa and Nerayo, Jerusalem and Evans-Riera, Lilly and Nielsen, Brittany and Krystal, Andrew D and O'Donovan, Aoife and Gard, David E and Woolley, Josh D},
  title = {An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression},
  journal = {The Journal of Clinical Psychiatry},
  year = {2026},
  doi = {10.4088/jcp.25m16227}
}
Kostenlos starten →